South Africa to revise AIDS control program to address extensively drug-resistant tuberculosis

NewsGuard 100/100 Score

South Africa is taking steps to revise its HIV/AIDS control program in an effort to combat the spread of extensively drug-resistant tuberculosis, TB that is resistant to first- and second-line drugs, Nomonde Xundu, the Department of Health's chief director for HIV and TB, said on Thursday, Reuters reports.

XDR-TB could exacerbate the HIV/AIDS epidemic in South Africa, where about five million out of a population of 45 million people are HIV-positive, and as many as 1,000 people die of AIDS-related complications daily, according to Reuters.

About 183 people, most of whom were HIV-positive, have died from XDR-TB in South Africa since September 2006.

Health planners are investigating ways to address HIV/TB coinfection and TB screening before launching a new AIDS control strategy in March, Xundu said.

Health Minister Manto Tshabalala-Msimang said the "biggest challenge" remains poor treatment adherence among people with TB.

She added that none of the people living with XDR-TB offered counseling in the country has declined treatment and that the government does not believe compulsory isolation is necessary (Reuters, 2/15).

Tshabalala-Msimang also said that the health department plans to strengthen the DOTS strategy to prevent the spread of multi-drug resistant and XDR-TB and will continue to collaborate with local and international experts to find ways to control the spread of XDR-TB (SAPA/iAfrica.com, 2/16).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Leveraging cancer therapies to combat tuberculosis